Krystal Biotech
KRYS
113 hedge funds and large institutions have $1.27B invested in Krystal Biotech in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 29 reducing their positions, and 11 closing their positions.
218% more call options, than puts
Call options by funds: $4.55M | Put options by funds: $1.43M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
83% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 29
52% more capital invested
Capital invested by funds: $836M → $1.27B (+$432M)
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
5% more funds holding
Funds holding: 108 → 113 (+5)
3.62% more ownership
Funds ownership: 70.6% → 74.22% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$92.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$28M |
| 3 |
AG
Artal Group
Luxembourg
|
+$19.1M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$11.4M |
| 5 |
JP Morgan Chase
New York
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.1M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.06M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$4.75M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$4.01M |
| 5 |
Goldman Sachs
New York
|
-$2.38M |
KRYS Hedge Fund Activity: Q1 2021 in Review
113 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2021, worth a combined $1.27B — up 52% from $836M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KRYS positions and 11 closed out — a net gain of 5 holders — while 53 added to existing stakes and 29 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $92.4M. The largest seller was Point72 Asset Management, cutting an estimated $24.1M.
- 113 institutional investors held Krystal Biotech (KRYS) as of Q1 2021, up from 108 in Q4 2020.
- Funds reported $1.27B of Krystal Biotech stock for Q1 2021, up 52% quarter-over-quarter.
- 16 funds opened new Krystal Biotech positions in Q1 2021 and 11 closed out, a net change of +5 holders.
- The largest Krystal Biotech buyer in Q1 2021 was Lord, Abbett & Co, an estimated $92.4M added.
- The largest Krystal Biotech seller in Q1 2021 was Point72 Asset Management, an estimated $24.1M sold.
Based on aggregated 13F filings for Q1 2021.